Detalhe da pesquisa
1.
Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.
Circulation
; 143(7): 673-684, 2021 02 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-33587659
2.
Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial.
Eur Heart J
; 42(17): 1698-1706, 2021 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33760027
3.
Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial.
Circulation
; 140(22): 1792-1801, 2019 11 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-31597460
4.
Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48.
Circulation
; 139(6): 760-771, 2019 02 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30586727
5.
Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial.
Eur Heart J
; 40(19): 1541-1550, 2019 05 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-30624719
6.
Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate.
Circulation
; 131(1): 82-90, 2015 Jan 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-25403645
7.
Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: A multicenter feasibility study.
Vasc Med
; 21(4): 361-8, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27165711
8.
Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal.
Crit Care
; 20(1): 273, 2016 Sep 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-27659071
9.
Serial assessment of biomarkers and heart failure outcomes in patients with atrial fibrillation.
Eur J Heart Fail
; 25(6): 832-841, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36987929
10.
Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48.
Eur Heart J Cardiovasc Pharmacother
; 8(7): 695-706, 2022 Sep 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34962979
11.
Edoxaban versus Warfarin in Patients with Atrial Fibrillation at the Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 Trial.
Thromb Haemost
; 121(2): 140-149, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32920808
12.
Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial.
J Clin Neurosci
; 86: 294-300, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33446422
13.
Efficacy and safety of edoxaban in patients with diabetes mellitus in the ENGAGE AF-TIMI 48 trial.
Int J Cardiol
; 304: 185-191, 2020 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32008850
14.
Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease.
J Am Coll Cardiol
; 74(2): 179-189, 2019 07 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-31296289
15.
Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban.
Thromb Haemost
; 117(2): 238-245, 2017 01 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-27853809